Showing 801-810 of 9129 results for "".
Which Probiotic for Which Disease? Part 2
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-2/23596/The conclusion of this 2-part series reviews the research for probiotics in the management of AD, acne, and psoriasis.Vitamin D and Psoriasis
https://practicaldermatology.com/topics/practice-management/vitamin-d-and-psoriasis/21470/New findings suggest a relationship between psoriasis and vitamin D deficiency, but larger details are still unknown.Vitiligo: An Update on Treatment Options
https://practicaldermatology.com/topics/skin-of-color/vitiligo-an-update-on-treatment-options/23995/From phototherapy to immunosuppresants to topical therapies, there are a number of treatment options for vitiligo.Investigational Oral Treatments for Psoriasis: A Review of Phase 2 and 3 Trials
https://practicaldermatology.com/topics/psoriasis/investigational-oral-treatments-for-psoriasis-a-review-of-phase-2-and-3-trials/23318/Although biologic medications have proven to be highly effective in the treatment of psoriasis, there remains a need for oral medications that offer similar success rates. Here’s a look in the pipeline.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://practicaldermatology.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Pruritus In PN and AD: Challenge How You Manage Itch
https://practicaldermatology.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.